Mizuho Securities Upgrades Jazz Pharmaceuticals (JAZZ) to Buy on Xyrem Settlements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 214.76 +2.79 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $211.97 | 52 Week High | $160.00 | |||
| Open | $211.38 | 52 Week Low | $95.80 | |||
| Day High | $215.20 | P/E | 39.92 | |||
| Day Low | $210.26 | EPS | $5.38 | |||
| Volume | 490,189 | |||||
